ClinicaliQ Trial Snapshot
- A Safety and Efficacy Study of hu14 in High-Risk Neuroblastoma Patients — Recruiting • Phase II / Phase III • Oncology • NCT07549321.
- Trial testing a new antibody drug combined with chemotherapy to treat high-risk neuroblastoma in young children.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
Neuroblastoma is the most common type of solid cancer found outside the brain in young children. Generally, it affects children younger than 5 years old, with the average age when it is found being just 2 years. Most patients have 'high-risk' disease, with spread of the disease to different sites (metastases). This multinational study aims to find out how effective and safe the treatment of a monoclonal anti-GD2 antibody hu14.18K322A (daretabart) is when used together with chemotherapy to treat children and young people who have high-risk neuroblastoma. Conditions: High-Risk Neuroblastoma…